Chimeric Antigen Receptor (CAR) T Cell Immunotherapy
CAR-T cell immunotherapy represents one of a major breakthrough in cancer research.For decades, the cornerstones of cancer treatment have been chemotherapy, surgery, and radiation therapy. Over the past decade, targeted therapies like trastuzumab (Herceptin) and imatinib (Gleevec) – drugs that target cancer cells by homing in on specific molecular changes observed primarily in those cells have also become standard treatment options for various types of cancer. Currently, research and development around anti-cancer immunotherapies is on rise. These therapies hold a potential to harness the utilize patients’ own immune system to combat diseases.
The CAR-T cell therapy, a form of immunotherapy, is a novel adoptive antitumor treatment. Ideally, CAR-T cells can particularly localize and destroy tumor cells by interacting with the tumor specific antigens located on surface of tumor cell. Current research studies showed that various tumor specific antigens can act as target antigensfor CAR-T cells, for instance, the type III variant epidermal growth factor receptor and human epidermal growth factor receptors are considered as ideal targets for its aberrant expression on the cell surface of various tumor types.
CAR-T cell therapy showed promising results in the treatment of haematological malignancies and solid tumors. The third generation of CAR-T cell therapy demonstrates increased antitumor cytotoxicity and persistence through modifying the structureof CAR-T cells. In this report, we mentioned the preclinical and clinical progress of CAR-T cells targeting various variants including EGFR, human epidermal growth factor receptor 2 (HER2), and mesothelin (MSLN).
The manufacturing of CD19 CAR T cell immunotherapy CTL019 is in a way which will reform the process of using the CAR T cell therapy globally. The anticipation of regulatory and manufacturing challenges before they rise and proactively addressing the disquiets helps to hasten the process of bringing this promising novel approach to more patients in future. Few of other promising CAR T cell candidates currently in the pipeline are KTE-C19, JCAR020, JCAR 024, JCAR015, JCAR017, UCART19, S68587, UCART123, MB-101, bb2121, PCAR-119, anti-CD19 CAR-NK cells, MB-102, AU-101, huCART19, huCTL019, BPX-401 (CIDeCAR), OXB-302, ICG-122, CD4CAR, ICG-124, CD5CAR, ICG-142, ICG-140, ICG-138/ICG-139, ICG-136.
Scope of The Report
The report provides
Provides in-depth insights about active Chimeric Antigen Receptor (CAR) T cell pipeline drug candidates
Offers an extensive pipeline product coverage with demarcation by various stages of development from NDA filings to discovery
Provides pipeline assessment by cancer type
Includes coverage of detailed pipeline drug profiles, which include product description, chemical information, MOA, licensors and collaborators, development partner
Analyzes key players involved in clinical research and development of the Chimeric Antigen Receptor (CAR) T cell immunotherapy
Provides the coverage of key news related to Chimeric Antigen Receptor (CAR) T cell immunotherapy, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates
Why should you buy the report?
- To gain erudite insights about the Chimeric Antigen Receptor (CAR) T cell immunotherapypipeline landscape
- To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine
- To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market
- To identify competitors and design strategic initiatives for drug development activities
- To understand the market and choose right partners for strategic collaborations
- To obtain informed updates on drug termination/drug discontinuation